Loading
A phase 1/2 trial of Dual-target CAR-NK cells in HER2-positive breast cancer and triple-negative breast cancer, run by Beijing Biotech, now recruiting.
Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC is a phase 1/2 interventional study registered as NCT07510802 by Beijing Biotech, with 60 participants planned, started 2026-02-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: Dual-target CAR-NK cells and Lymphodepleting.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.